Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Factors associated with unreported tuberculosis cases in Spanish hospitals.

Morales-García C, Rodrigo T, García-Clemente MM, Muñoz A, Bermúdez P, Casas F, Somoza M, Milá C, Penas A, Hidalgo C, Casals M, Caylá JA; Working Group on Under-reporting of Tuberculosis in Spain.

BMC Infect Dis. 2015 Jul 29;15(1):295. doi: 10.1186/s12879-015-1047-0.

2.

Predicting the Development of Tuberculosis with the Tuberculin Skin Test and QuantiFERON Testing.

Altet N, Dominguez J, Souza-Galvão ML, Jiménez-Fuentes MÁ, Milà C, Solsona J, Soriano-Arandés A, Latorre I, Lara E, Cantos A, Ferrer MD, Orcau À, Ruiz-Manzano J, Caylà J.

Ann Am Thorac Soc. 2015 May;12(5):680-8. doi: 10.1513/AnnalsATS.201408-394OC.

PMID:
25699406
3.

Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis.

Serra-Vidal MM, Latorre I, Franken KL, Díaz J, de Souza-Galvão ML, Casas I, Maldonado J, Milà C, Solsona J, Jimenez-Fuentes MA, Altet N, Lacoma A, Ruiz-Manzano J, Ausina V, Prat C, Ottenhoff TH, Domínguez J.

Front Microbiol. 2014 Oct 8;5:517. eCollection 2014.

4.

Resistance to first-line antituberculosis drugs in Spain, 2010-2011. RETUBES Study.

Blanquer R, Rodrigo T, Casals M, Ruiz Manzano J, García-García JM, Calpe JL, Valencia E, Pascual T, Mir I, Jiménez MÁ, Cañas F, Vidal R, Penas A, Caylà JA; Working Group of the Integrated Programme for Research in Tuberculosis in Spain.

Arch Bronconeumol. 2015 Jan;51(1):24-30. doi: 10.1016/j.arbres.2014.06.001. Epub 2014 Jul 11. English, Spanish.

5.

Correlation between tuberculin skin test and IGRAs with risk factors for the spread of infection in close contacts with sputum smear positive in pulmonary tuberculosis.

de Souza-Galvão ML, Latorre I, Altet-Gómez N, Jiménez-Fuentes MÁ, Milà C, Solsona J, Seminario MA, Cantos A, Ruiz-Manzano J, Domínguez J.

BMC Infect Dis. 2014 May 13;14:258. doi: 10.1186/1471-2334-14-258.

6.

Monitoring changes in anti-tuberculosis treatment: associated factors determined at the time of diagnosis.

Altet MN, Vidal R, Milá C, Rodrigo T, Casals M, Mir I, Ruiz-Manzano J, Jiménez-Fuentes MA, Sánchez F, Maldonado J, Blanquer R, de Souza-Galväo ML, Solsona J, Azlor E, Díaz D, Calpe JL, Caylá JA.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1435-41. doi: 10.5588/ijtld.13.0182.

PMID:
24125447
7.

A predictive scoring instrument for tuberculosis lost to follow-up outcome.

Rodrigo T, Caylà JA, Casals M, García-García JM, Caminero JA, Ruiz-Manzano J, Blanquer R, Vidal R, Altet N, Calpe JL, Penas A; Working Group on Completion of Tuberculosis Treatment in Spain.

Respir Res. 2012 Sep 2;13:75. doi: 10.1186/1465-9921-13-75.

8.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium.

J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

9.

Predictors of death among patients who completed tuberculosis treatment: a population-based cohort study.

Millet JP, Orcau A, Rius C, Casals M, de Olalla PG, Moreno A, Nelson JL, Caylà JA; Barcelona Tuberculosis Working Group.

PLoS One. 2011;6(9):e25315. doi: 10.1371/journal.pone.0025315. Epub 2011 Sep 28.

10.

Social, clinical and microbiological differential characteristics of tuberculosis among immigrants in Spain.

García-García JM, Blanquer R, Rodrigo T, Caylà JA, Caminero JA, Vidal R, Casals M, Ruiz-Manzano J; Working Group on Completion of Tuberculosis Treatment in Spain.

PLoS One. 2011 Jan 20;6(1):e16272. doi: 10.1371/journal.pone.0016272.

11.

Diagnosing TB infection in children: analysis of discordances using in vitro tests and the tuberculin skin test.

Altet-Gómez N, De Souza-Galvao M, Latorre I, Milà C, Jiménez MA, Solsona J, Cantos A, Zamora JJ, Ruiz-Manzano J, Ausina V, Domínguez J.

Eur Respir J. 2011 May;37(5):1166-74. doi: 10.1183/09031936.00022710. Epub 2010 Aug 20.

12.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium.

PLoS One. 2010 May 20;5(5):e10753. doi: 10.1371/journal.pone.0010753.

13.

[On the way to shortening tuberculosis treatments: clinical trials of the Unitat d' Investagació en Tuberculosi de Barcelona supported by the Centers for Disease Control and Prevention].

Moreno A, Sánchez F, Nelson J, Miró JM, Caylà JA; Grupo de Trabajo de la UITB-TBTC (site 31).

Gac Sanit. 2010 Mar-Apr;24(2):171.e1-6. doi: 10.1016/j.gaceta.2009.08.008. Epub 2009 Dec 10. Spanish.

14.

Tuberculosis treatment adherence and fatality in Spain.

Caylà JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, García JM, Blanquer R, Casals M; Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE).

Respir Res. 2009 Dec 1;10:121. doi: 10.1186/1465-9921-10-121.

15.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.

PMID:
19406981
16.

[Incidence and preventability of adverse events in patients hospitalised in three Colombian hospitals during 2006].

Gaitán-Duarte H, Eslava-Schmalbach J, Rodríguez-Malagon N, Forero-Supelano V, Santofimio-Sierra D, Altahona H; Grupo de Evaluación de Tecnologías y Políticas en Salud.

Rev Salud Publica (Bogota). 2008 Mar-May;10(2):215-26. Spanish.

17.

T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment.

Domínguez J, De Souza-Galvão M, Ruiz-Manzano J, Latorre I, Prat C, Lacoma A, Milà C, Jiménez MA, Blanco S, Maldonado J, Altet N, Ausina V.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51. doi: 10.1016/j.diagmicrobio.2008.09.010. Epub 2008 Nov 21.

PMID:
19026511
18.

Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis.

Domínguez J, Ruiz-Manzano J, De Souza-Galvão M, Latorre I, Milà C, Blanco S, Jiménez MA, Prat C, Lacoma A, Altet N, Ausina V.

Clin Vaccine Immunol. 2008 Jan;15(1):168-71. Epub 2007 Oct 31.

19.

Tuberculosis screening among immigrants holding a hunger strike in churches.

García de Olalla P, Caylà JA, Milá C, Jansà JM, Badosa I, Ferrer A, Ros M, Gómez i Prat J, Armengou JM, Alonso E, Alcaide J.

Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S412-6.

PMID:
14677831
20.

Screening for tuberculosis upon admission to shelters and free-meal services.

Solsona J, Caylà JA, Nadal J, Bedia M, Mata C, Brau J, Maldonado J, Milà C, Alcaide J, Altet N, Galdós-Tangüis H.

Eur J Epidemiol. 2001;17(2):123-8.

PMID:
11599684
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk